Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
Abbott (NYSE: ABT) has commenced the TactiFlex PAF IDE study to evaluate its investigational TactiFlex Ablation Catheter for treating paroxysmal atrial fibrillation (PAF). With over 16 million individuals affected by AFib globally, the study aims to enroll 355 patients across multiple sites worldwide. The catheter employs contact force technology for enhanced procedural effectiveness. Presently, the device is under clinical evaluation and not yet commercially available, aligning with Abbott's commitment to providing advanced medical solutions for improving patient care.
- Initiation of TactiFlex PAF IDE study, highlighting Abbott's innovation in treating atrial fibrillation.
- The TactiFlex Ablation Catheter uses advanced contact force technology, improving efficacy in ablation procedures.
- Positive feedback from medical professionals regarding the TactiFlex device's potential.
- The TactiFlex Ablation Catheter is currently not commercially available, which limits immediate market impact.
ABBOTT PARK, Ill., Aug. 4, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat. The study will evaluate the performance of the investigational TactiFlex™ Ablation Catheter, Sensor Enabled™ (SE) for people whose atrial fibrillation (AFib) symptoms are unable to be managed by medication.
More than 16 million people globally are impacted by recurrent AFib, episodes of sporadic, irregular heartbeats when the heart's upper chambers beat out of sync with the lower chambers. People suffering from AFib face a number of challenges to their quality of life, including episodes of dizziness, fatigue and shortness of breath. Long term, they also face increased risk of stroke or heart failure.
The TactiFlex PAF IDE study will enroll 355 patients at multiple sites worldwide. Patients enrolled in the trial will receive an ablation procedure using Abbott's TactiFlex Ablation Catheter, SE. Data collected from the study will be submitted to support global regulatory approvals.
Physicians use tools, such as contact force technology, during ablation procedures to help them apply the right amount of pressure to the heart tissue to improve procedural effectiveness. Additionally, physicians use magnetically sensor enabled technology, such as the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, for precise location and navigation within the heart.
"The TactiFlex device builds on prior generations of successful technology, giving me confidence that Abbott will continue providing options to effectively treat people living with recurrent episodes of atrial fibrillation," said Prof. Prash Sanders, director of Centre for Heart Rhythm Disorders at The Royal Adelaide Hospital in Adelaide, South Australia.
The start of the TactiFlex PAF IDE trial is among a series of product-focused activities from Abbott designed to improve patient care and meet the needs of electrophysiologists around the world. The company also recently secured U.S. Food and Drug Administration (FDA) and CE Mark approval for the EnSite™ LiveView Dynamic Display. LiveView is designed to allow data from the Advisor HD Grid mapping catheter to be visualized in real time during cardiac ablation procedures. The Advisor HD Grid catheter is designed to capture information often missed with traditional mapping catheters.
"Abbott is focused on bringing innovation to physicians that can improve how people with atrial fibrillation are treated. The TactiFlex Ablation Catheter, SE brings the best of Abbott's ablation technologies into a single catheter," said Mike Pederson, senior vice president of Abbott's electrophysiology and heart failure businesses.
The TactiFlex Ablation Catheter, SE is being clinically evaluated as part of the TactiFlex PAF IDE – a global study – and is not yet commercially available.
About Cardiac Ablation:
Cardiac ablation is a minimally invasive procedure that can treat abnormally fast heartbeats by creating lesions (ablating) in small areas of heart tissue that a physician has identified as causing the arrhythmia. When physicians use catheter ablation to treat cardiac arrhythmias, long flexible tubes — called catheters — are inserted into the heart to study the arrhythmia and to deliver radio frequency (RF) energy. Heat generated from the RF energy creates a scar on the tissue where the abnormal heartbeats originate; this type of ablation has become the gold standard for treating AFib. As a result, this tissue is no longer capable of conducting or sustaining the arrhythmia.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
View original content:http://www.prnewswire.com/news-releases/abbott-announces-start-of-study-to-evaluate-new-device-to-treat-recurrent-atrial-fibrillation-301105138.html
SOURCE Abbott
FAQ
What is the TactiFlex PAF IDE study by Abbott?
How many patients will be enrolled in the TactiFlex PAF IDE study?
When was the TactiFlex PAF IDE study announced?
What does the TactiFlex Ablation Catheter aim to treat?
What is Abbott's stock symbol?
